Cozad Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.27M | Buy |
6,560
+83
| +1% | +$16K | 0.1% | 195 |
|
|
2025
Q4 | $1.19M | Hold |
6,477
| – | – | 0.09% | 200 |
|
|
2025
Q3 | $994K | Buy |
6,477
+97
| +2% | +$14.7K | 0.08% | 217 |
|
|
2025
Q2 | $892K | Sell |
6,380
-3,052
| -32% | -$428K | 0.08% | 213 |
|
|
2025
Q1 | $1.39M | Sell |
9,432
-7,770
| -45% | -$1.12M | 0.14% | 155 |
|
|
2024
Q4 | $2.25M | Sell |
17,202
-753
| -4% | -$105K | 0.21% | 117 |
|
|
2024
Q3 | $2.8M | Sell |
17,955
-2,500
| -12% | -$404K | 0.27% | 100 |
|
|
2024
Q2 | $3.19M | Buy |
20,455
+4,200
| +26% | +$632K | 0.32% | 86 |
|
|
2024
Q1 | $2.2M | Buy |
16,255
+130
| +0.8% | +$17.2K | 0.23% | 116 |
|
|
2023
Q4 | $2.17M | Buy |
16,125
+2,725
| +20% | +$354K | 0.25% | 110 |
|
|
2023
Q3 | $1.81M | Buy |
13,400
+2,300
| +21% | +$314K | 0.24% | 113 |
|
|
2023
Q2 | $1.59M | Buy |
11,100
+524
| +5% | +$77.1K | 0.2% | 128 |
|
|
2023
Q1 | $1.47M | Buy |
10,576
+2,115
| +25% | +$285K | 0.19% | 140 |
|
|
2022
Q4 | $1.15M | Buy |
8,461
+4,288
| +103% | +$538K | 0.16% | 157 |
|
|
2022
Q3 | $458K | Buy |
4,173
+409
| +11% | +$51.9K | 0.07% | 225 |
|
|
2022
Q2 | $497K | Hold |
3,764
| – | – | 0.08% | 216 |
|
|
2022
Q1 | $499K | Hold |
3,764
| – | – | 0.07% | 227 |
|
|
2021
Q4 | $439K | Hold |
3,764
| – | – | 0.06% | 236 |
|
|
2021
Q3 | $452K | Buy |
3,764
+34
| +0.9% | +$3.96K | 0.07% | 226 |
|
|
2021
Q2 | $447K | Sell |
3,730
-1,095
| -23% | -$120K | 0.07% | 226 |
|
|
2021
Q1 | $480K | Buy |
4,825
+150
| +3% | +$15.1K | 0.08% | 217 |
|
|
2020
Q4 | $467K | Sell |
4,675
-91
| -2% | -$9.64K | 0.08% | 209 |
|
|
2020
Q3 | $522K | Buy |
4,766
+539
| +13% | +$60K | 0.1% | 194 |
|
|
2020
Q2 | $447K | Sell |
4,227
-1,256
| -23% | -$130K | 0.09% | 195 |
|
|
2020
Q1 | $490K | Sell |
5,483
-215
| -4% | -$20.2K | 0.17% | 130 |
|
|
2019
Q4 | $568K | Sell |
5,698
-155
| -3% | -$14.6K | 0.15% | 135 |
|
|
2019
Q3 | $522K | Buy |
5,853
+160
| +3% | +$13.9K | 0.15% | 138 |
|
|
2019
Q2 | $470K | Sell |
5,693
-77
| -1% | -$6.04K | 0.14% | 147 |
|
|
2019
Q1 | $467K | Sell |
5,770
-200
| -3% | -$15.8K | 0.14% | 149 |
|
|
2018
Q4 | $453K | Buy |
5,970
+24
| +0.4% | +$1.87K | 0.16% | 141 |
|
|
2018
Q3 | $471K | Sell |
5,946
-240
| -4% | -$18.2K | 0.14% | 140 |
|
|
2018
Q2 | $434K | Buy |
+6,186
| New | +$445K | 0.14% | 141 |
|
Other funds holding AZN
IA
VCM
VAM
Cozad Asset Management's AZN Position: Q1 2026 in Review
Cozad Asset Management increased its AstraZeneca (AZN) stake by 1.3% in Q1 2026, buying an estimated $16K and bringing the position to 6,560 shares worth $1.27M. The position accounts for 0.1% of the portfolio, ranked #195.
Cozad Asset Management first reported a position in AZN in Q2 2018 and has held it in 32 quarters since. The position peaked at $3.19M in Q2 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Cozad Asset Management held 6,560 shares of AstraZeneca worth $1.27M as of Q1 2026.
- Cozad Asset Management bought 83 AstraZeneca shares in Q1 2026, an estimated $16K.
- AstraZeneca made up 0.1% of Cozad Asset Management's portfolio in Q1 2026, its #195 holding.
- Cozad Asset Management first reported a position in AstraZeneca in Q2 2018 and has held it in 32 quarters since.
- Cozad Asset Management's AstraZeneca position peaked at $3.19M in Q2 2024.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Cozad Asset Management's 13F filing for Q1 2026, filed 28 May 2026.